The role of ranitidine in the prevention of weight gain

The role of ranitidine in the prevention of olanzapine induced weight gain

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201009112181N5

Enrollment

Registered

2010-10-26

Start date

2008-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: obesity. Condition 2: Schizophrenia. Condition 3: Schizoaffective disorders. Drug-induced obesity Schizophrenia Schizoaffective disorders

Interventions

Intervention 1: Intervention group: tab ranitidine 150mg, 4 tab per day, orally, for 16 weeks. Intervention 2: Control group: placebo with the same shape, size and taste, 4 tab, orally, for 16 weeks.

Treatment - Drugs

Placebo

Intervention group: tab ranitidine 150mg, 4 tab per day, orally, for 16 weeks

Control group: placebo with the same shape, size and taste, 4 tab, orally, for 16 weeks

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Taking olanzapine for thought disorder, Hospitalization for over 16 weeks, signing informed written consent Exclusion criteria: The physical co-morbidity, Simultaneous taking of drugs with weight gain side effect, Special diets

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Body weight. Timepoint: Before and 16 weeks after intervention. Method of measurement: Weight Scale(kg).	—

Secondary

Measure	Time frame
Ranitidine side effects. Timepoint: Weekly. Method of measurement: drugs side effects questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Alireza Ghanepoor

Tabriz University of Medical Sciences

dr.ghanepoor@gmail.com+98 41 1380 4486

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026